Serious concerns have emerged about falsified weight loss medicines circulating in the UK market, posing significant health risks to Britons. GP Dr Bhavini Shah warned that undeclared ingredients in ...

With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more ...

With more than 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

The much hyped weightloss drug Wegovy, also marketed as Ozempic, is expected to be in high demand when it becomes available in New Zealand from tomorrow. But the drug is unfunded so users hoping to ...

Does lemon water really burn fat? Or is it just another wellness myth? ???? In this fact-check video, top health and nutrition experts bust 15 of the most common weight loss myths ...

The TGA urged doctors to warn Ozempic users to 'be careful' and check the dose before administering it. Earlier this month, official data revealed more than 100 deaths in the United Kingdom had now ...

Sunday on PBS News Weekend, three years after the end of Roe v. Wade, a decades-old movement is exploring new ways to circumvent abortion bans and restrictions. A former FDA head discusses the science ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with sustained ...

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

McCormick & Company, Incorporated (NYSE:MKC) is one of the Jim Cramer Warns Viewers About FOMO & Discusses These 19 Stocks.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.